• 1
    Sheu BS, Kao AW, Cheng HC, Huang SF, Chen TW, Lu CC. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005; 21: 2838.
  • 2
    Hedrick PW (ed.). Measures of genetic variation. In: Genetics of Populations, 2nd edn. Sudbury: Jones and Bartlett, 2000: 477.
  • 3
    Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7: 594.
  • 4
    Xie HG. Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the Chinese population. Life Sci 2000; 66: PL17581.
  • 5
    Chen MC, Wang LY, Hu CT, Liu TT, Lin TC, Lin YK. Distribution of CYP2C19*2, Principal Poor Metabolizer Genotype of Proton Pump Inhibitor in Hualien. Gastroenterological Journal of Taiwan 2005; 22: 86. (in Chinese).